[EN] 1,2,4 -TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA<br/>[FR] 1,2,4-TRIAZOLES COMME MODULATEURS ALLOSTÉRIQUES DE L'ACTIVITÉ DES RÉCEPTEURS MGLU5 POUR LE TRAITEMENT DE LA SCHIZOPHRÉNIE OU DE LA DÉMENCE
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2013083741A1
公开(公告)日:2013-06-13
This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.
This invention relates to novel pyrazolopyrimidines and their use as metabotropic glutamate receptor antagonists (mGlu5 receptor antagonists), pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of mGlu5 receptor mediated disorders.
This invention relates to novel pyrazolopyrimidines and their use as metabotropic glutamate 5 receptor antagonists (mGlu5 receptor antagonists), pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of mGlu5 receptor mediated disorders.
Novel mGluR antagonists and a method for their synthesis
申请人:——
公开号:US20020045635A1
公开(公告)日:2002-04-18
The invention relates to nitro- and cyano-1,2,4,5-tetrahydro-heterocycloazepinyl pyrimidine derivatives as well as their pharmaceutically acceptable salts. The invention further relates to medicaments containing such compounds and a process for the preparation of such compounds. The compounds of the invention are group I mGluR antagonists and are therefore useful for the control or prevention of acute and/or chronic neurological disorders.